Clinical Trial Update: Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and efficacy study of DX-2930 (SHP643) for preventing acute angioedema attacks in patients with Hereditary Angioedema has completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• DX-2930 (SHP643) (DX-2930)

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: COMPLETED | Results posted: 2020-05-11